UNSPSC 51352408: Estrogens/estrone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS300. This VA Drug Class (HS300) classifies this compound as belonging to the group ESTROGENS.

UNSPSC 51352408 Estrogens/estrone is a Commodity code covering pharmaceutical products sold directly to state and local health agencies, purchasing cooperatives, and institutional buyers. State and local procurement under this code focuses on securing generic estrogen and estrone products for distribution through state health benefit programs, Medicaid agencies, and cooperative purchasing arrangements. The issuing bodies include state health departments and agencies (notably the Texas Health and Human Services Commission and Minnesota Department of Administration), as well as multistate cooperative purchasing alliances that aggregate demand across participating state and local jurisdictions. Recent solicitations show state procurement offices moving toward direct manufacturer relationships and competitive supplier frameworks to manage pharmaceutical costs and ensure reliable product availability across multiple authorized distribution channels.

Geographic activity centers on Texas and Minnesota, with broader participation through multistate cooperatives serving multiple states including Oregon. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in March 2026 to assess vendor capacity for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting strategies and negotiated net pricing models outside traditional pharmacy benefit manager and group purchasing organization arrangements. The Minnesota Department of Administration, through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with awarded vendors effective July 1, 2026. The MMCAP procurement requires submission of detailed product information, certification of cGMP and Drug Supply Chain Security Act compliance, contractual relationships with at least two of three authorized wholesalers, and competitive pricing with a 3 percent administrative fee obligation.